The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn’s Disease: Experience from a Tertiary Medical Center in China

Table 2

Efficacy assessment of IFX or AZA monotherapy in maintaining therapy of Crohn’s disease, (%).

Efficacy assessment	IFX monotherapy group	IFX-AZA sequential therapy group	All	value
Deep remission at week 84	18 (81.8)	26 (45.6)	44 (55.7)	0.004
Deep remission at week 138	17 (77.3)	21 (36.8)	38 (48.1)	0.001
Clinical remission at week 57	21 (95.5)	52 (91.2)	73 (92.4)	0.871
Clinical remission at week 84	20 (90.9)	49 (86.0)	69 (87.3)	0.830
Clinical remission at week 111	19 (86.4)	48 (84.2)	67 (84.8)	0.999
Clinical remission at week 138	19 (86.4)	45 (78.9)	64 (81.0)	0.665
Complete endoscopic remission at week 84	18 (81.8)	27 (47.4)	45 (57.0)	0.012
Complete endoscopic remission at week 138	17 (77.3)	22 (38.6)	39 (49.4)	0.002
Endoscopic remission at week 84	21 (95.5)	47 (82.5)	68 (86.1)	0.257
Endoscopic remission at week 138	19 (86.4)	45 (78.9)	64 (81.0)	0.665
Endoscopic improvement at week 84	21 (95.5)	53 (93.0)	74 (93.7)	0.999
Endoscopic improvement at week 138	20 (90.9)	52 (91.2)	72 (91.1)	0.999